Wells Fargo Sticks to Their Buy Rating for Editas Medicine (EDIT)
Leerink Partners Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8
Editas Medicine (EDIT) Receives a Hold From RBC Capital
JonesTrading Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $13
Editas Medicine Hold Rating With Revised Price Target Amidst Mixed Financial Signals
Buy Rating for Editas Medicine Backed by Strong Q2 Performance and Promising CRISPR Pipeline
Barclays Remains a Hold on Editas Medicine (EDIT)
Buy Rating on Editas Medicine as R&D Progress Signals Market Potential for Sickle Cell and Thalassemia Treatments
Editas Medicine Price Target Raised to $15.00/Share From $13.00 by B of A Securities
Editas Medicine Analyst Ratings
Truist Securities Adjusts Price Target on Editas Medicine to $12 From $20, Maintains Buy Rating
TD Cowen Sticks to Their Buy Rating for Editas Medicine (EDIT)
Editas Medicine Analyst Ratings
Editas Medicine Analyst Ratings
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
Editas Medicine Analyst Ratings
Editas Medicine Upgraded at J.P. Morgan on Recent Weakness
Editas Medicine's Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy Rating
Maintaining a Hold: Editas Medicine Awaits Key Clinical Trial Results and Market Positioning